Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps his Department is taking to help tackle health inequalities in liver disease in Blackpool.

Liver disease is a broad term for several conditions affecting the liver and pancreas and the Government is taking decisive action to tackle ill health and shift the focus on diseases such as liver disease from treatment to prevention.

The most prevalent cause of liver-related ill health and death is alcohol-related liver disease. From 2026/27, all alcohol and drug treatment and recovery funding will be channelled through the Public Health Grant, with ringfenced funding in which Blackpool Council will receive £4,554,578 in 2026/27 and indicative totals of £4,647,350 and £4,737,845 for 2027/28 and 2028/29 respectively. The Department has also published the United Kingdom’s first clinical guidelines on alcohol treatment which include guidance on early identification of liver disease and treating alcohol dependence in people with liver disease. To help people make healthier choices about alcohol we are making it a legal requirement for alcohol labels to display health warnings and consistent nutritional information.

Locally, Blackpool Teaching Hospital’s Liver Service has recently achieved micro‑elimination of hepatitis C, with all drug and alcohol services across Lancashire now declared micro‑eliminated. The region’s Liver Health Check Team supports earlier detection of liver disease by referring at‑risk individuals, including those with high body mass index, diabetes, or high alcohol consumption for community fibroscans available in general practices (GPs), community venues, and via mobile units.

NHS England’s liver transformation programme focusses on awareness, prevention, diagnosis, detection, and treatment of all forms of liver disease and has developed a data pack for regional commissioners using the Department’s Fingertips data to support this. It is for commissioners in integrated care boards to determine how best to use this information as part of local commissioning decisions. The National Institute for Health and Care Excellence is assessing new treatments for metabolic dysfunction-associated steatotic liver disease (MASLD), the broader term for fat buildup of the liver, which metabolic dysfunction-associated steatohepatitis (MASH) falls under. This includes resmetirom and semaglutide. Outputs and recommendations are expected to be published mid-2026.

As part of our 10-Year Health Plan, we are improving diets, reducing physical inactivity, and creating healthier environments so that fewer people reach the point of needing treatment for diseases such as MASH. This includes updating the standards behind the advertising and promotions restrictions on ‘less healthy’ food and drink, requiring all large food businesses to report against standardised metrics on the healthiness of food sales and getting millions moving more through our national movement campaign.